Aryl methyl benzoquinazolinine M1 receptor positive allosteric modulators
US8557832B2 · kind B2 · utility
0Cited by
1References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 19, 2009 |
| Grant date | Oct 15, 2013 |
| Priority date | — |
| Expiry date | Aug 27, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.